Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
1.
Scand J Infect Dis ; 44(5): 363-8, 2012 May.
Artigo em Inglês | MEDLINE | ID: mdl-22200089

RESUMO

BACKGROUND: Escherichia coli is a common cause of bacteraemia and is increasingly resistant to ciprofloxacin and gentamicin. The primary objective of this study was to investigate how often this leads to inadequate initial antimicrobial treatment. Secondary goals were to determine factors associated with inadequate empirical therapy and to assess its impact on mortality and length of stay. METHODS: All patients with an E. coli bacteraemia hospitalized in 2008 were identified retrospectively. Initial antimicrobial therapy and clinical outcomes of all patients with an isolate resistant to gentamicin and/or ciprofloxacin (cases) were compared to those of a group of randomly selected patients in whom a gentamicin and ciprofloxacin susceptible E. coli was isolated (controls). RESULTS: One hundred and thirty-six unique patients had E. coli bacteraemia. Of these, 34 patients were identified as cases and were compared to 34 controls. Among the cases, 97% of the E. coli was resistant to ciprofloxacin and 44% to gentamicin. Resistance to amoxicillin was high in both cases (94%) and controls (65%). In 41% of the cases initial antimicrobial therapy was inadequate, compared to only 3% in the controls. The majority of inadequately treated cases had a biliary focus (64%). Infections in cases were more often healthcare-associated than infections in controls (62% vs 26%). E. coli with the same resistance pattern had been isolated before in adequately treated cases more often than in inadequately treated cases. Mortality did not differ significantly between cases and controls. CONCLUSIONS: Neither ciprofloxacin nor amoxicillin should be used as empirical therapy in patients with a presumed E. coli bacteraemia.


Assuntos
Antibacterianos/farmacologia , Bacteriemia/mortalidade , Ciprofloxacina/farmacologia , Farmacorresistência Bacteriana , Escherichia coli/efeitos dos fármacos , Gentamicinas/farmacologia , Tempo de Internação/estatística & dados numéricos , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Antibacterianos/uso terapêutico , Bacteriemia/tratamento farmacológico , Bacteriemia/microbiologia , Estudos de Casos e Controles , Criança , Pré-Escolar , Ciprofloxacina/uso terapêutico , Escherichia coli/isolamento & purificação , Infecções por Escherichia coli/tratamento farmacológico , Infecções por Escherichia coli/microbiologia , Infecções por Escherichia coli/mortalidade , Feminino , Gentamicinas/uso terapêutico , Humanos , Lactente , Recém-Nascido , Estimativa de Kaplan-Meier , Masculino , Testes de Sensibilidade Microbiana , Pessoa de Meia-Idade , Países Baixos/epidemiologia , Adulto Jovem
2.
Immunol Lett ; 20(1): 59-61, 1989 Jan 15.
Artigo em Inglês | MEDLINE | ID: mdl-2714840

RESUMO

The anaerobic bacterium Campylobacter pylori (Cp) is thought to be associated with chronic gastritis. This paper presents clinical data underpinning this view. Five patients with histological chronic gastritis as determined by diagnostic endoscopy, which was associated with Cp as determined by positive biopsy cultures, all possessed statistically raised serum IgG ELISA titers to Cp during a longitudinal period of observation of 15 months. Treatment with the antibiotics amoxycillin (clamoxyl) or colloidal bismuth subcitrate (denol) eliminated Cp within one month. Associated with this, serum IgG ELISA titers were found to decrease sharply and rapidly. Tagamet and spiramycin had little effect. Although the data are preliminary, they support the assumed Cp involvement in chronic gastritis and suggest that specific serum IgG ELISA titers to Cp are useful parameters in monitoring disease status, exceeding bacteriological culture of biopsy specimens in speed and convenience.


Assuntos
Anticorpos Antibacterianos/biossíntese , Infecções por Campylobacter/imunologia , Campylobacter/imunologia , Gastrite/etiologia , Imunoglobulina G/biossíntese , Antibacterianos/uso terapêutico , Biópsia , Infecções por Campylobacter/tratamento farmacológico , Infecções por Campylobacter/microbiologia , Doença Crônica , Ensaio de Imunoadsorção Enzimática , Gastrite/tratamento farmacológico , Gastrite/microbiologia , Humanos , Estômago/microbiologia , Estômago/patologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA